© 1999 European Society of Cardiology
Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study
University of Hull, Department of Cardiology, Castle Hill Hospital Castle Rd, Cottingham, Kingston-upon-Hull, East Yorkshire, HU16 5JQ, UK
* Corresponding author. University of Hull, Castle Hill Hospital, Department of Cardiology, Castle Rd., Cottingham, Kingston-upon-Hull, East Yorkshire, HU16 5JQ, UK
 |
Abstract |
|---|
Background: The beneficial effect of ACE inhibitors on mortality has been established in a series of trials. However, in clinical practice, ACE inhibitors are commonly administered in doses much lower than those shown to be effective in the landmark trials.
Aims: This report describes the baseline characteristics of the patients recruited into the ATLAS study by age and gender sub-groups.
Methods: The ATLAS study compared the effects of ‘low’ dose (2.5–5.0 mg/day) to ‘high’ dose (32.5–55.0 mg/day) lisinopril in a double-blind study of 5164 patients with moderate to severe heart failure and left ventricular ejection fraction < 30% during a mean follow-up period of 46 months. The primary end-point was all cause mortality and the principal secondary end-point a composite of all-cause hospitalisation or all-cause mortality.
Results: Among patients with heart failure selected for the presence of left ventricular systolic function there were few differences among age groups or between genders. Older patients were not so heavy, were more likely to have ischaemic heart disease, hypertension and atrial fibrillation contributing to their heart failure and had a higher blood urea. Women were not so heavy as men. Age and gender had no major influence on mean ejection fraction or baseline treatment in the ATLAS study.
Conclusions: Weight and renal function may alter the plasma concentration of any given dose of an ACE inhibitor. Potential interactions between dose of lisinopril, weight and renal function will be explored after the study is completed.
Key Words: ACE inhibitors • Lisinopril • Patients with heart failure • Dose
1 On behalf of the ATLAS investigators. The ATLAS study is supported by Zeneca Pharmaceuticals.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P A Poole-Wilson, B F Uretsky, K Thygesen, J G F Cleland, B M Massie, and L Ryden Mode of death in heart failure: findings from the ATLAS trial Heart, January 1, 2003; 89(1): 42 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J G F Cleland Contemporary management of heart failure in clinical practice Heart, October 1, 2002; 88(90002): ii5 - 8. [Full Text] [PDF]
|
|
|
|
 |
|
 J.G.F. Cleland, K. Thygesen, B.F. Uretsky, P. Armstrong, J.D. Horowitz, B. Massie, M. Packer, P.A. Poole-Wilson, L. Ryden, and on behalf of the ATLAS investigators Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study Eur. Heart J., September 1, 2001; 22(17): 1601 - 1612. [Abstract] [PDF]
|
|
|
|
|
|
L Ryden, P.W Armstrong, J.G.F Cleland, J.D Horowitz, B.M Massie, M Packer, and P.A Poole-Wilson Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial Eur. Heart J., December 1, 2000; 21(23): 1967 - 1978. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Packer, P. A. Poole-Wilson, P. W. Armstrong, J. G. F. Cleland, J. D. Horowitz, B. M. Massie, L. Ryden, K. Thygesen, and B. F. Uretsky Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure Circulation, December 7, 1999; 100(23): 2312 - 2318. [Abstract] [Full Text] [PDF]
|
|